

Ref: FOI/GS/ID 6175

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

24 July 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Anti-VEGF treatment.

You asked:

*1. Within your Trust, how many patients, in the most recent 12-month period for which data are available, have received anti-VEGF treatment **for the first time** (i.e., excluding patients who previously had any anti-VEGF therapy)?*

2. Of these first-time patients, please provide a breakdown by the treatments listed below:

Aflibercept

Brolucizumab

Dexamethasone

Ranibizumab

All other anti-VEGF treatments

3. Of these first-time patients, how many were treated for Wet Age-Related Macular Degeneration (wAMD) by each treatment?

Aflibercept

Brolucizumab

Dexamethasone

Ranibizumab

All Other anti-VEGF treatments

Trust response:

Please see the following table:

Figures for April to April 2019-2020

	All indications	WAMD
Total Patients receiving anti-VEGF treatment for the first time	568	311
Breakdown by treatment		
Aflibercept	194	156
Brolucizumab	0	0
Dexamethasone	76	0
Ranibizumab	298	155
Fluocinolone Acetonide	0	0